Medicenna Therapeutics Corp. (MDNA.TO)
| Previous Close | 2.3200 |
| Open | 2.3700 |
| Bid | 2.8100 x N/A |
| Ask | 2.8500 x N/A |
| Day's Range | 2.2900 - 2.8500 |
| 52 Week Range | 0.2150 - 2.8900 |
| Volume | |
| Avg. Volume | 159,982 |
| Market Cap | 213.12M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | Jun 25, 2024 - Jul 01, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.56 |
GlobeNewswireMedicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma patient continues to show sustained 100% regression of target lesions Dose escalation in combination with KEYTRUDA® is now enrolling at the next higher dose of 90g/kg following absence of any dose limiting toxicities at 60g/kg MDNA11 shows significant increases in stemness, central and
- GlobeNewswire
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1 Trial at the Sachs 10th Annual Oncology Innovation Forum. The forum takes place on Friday, May 31st, 2024, as part of the clinical partnering and investment activities surrounding the 2024 American Society o
- Baystreet
Stocks in play: Medicenna Therapeutics Corp.
Announced today that the American Society of Clinical Oncology decided to reverse its decision and to ...
